Media releases

Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million

Idorsia announces a change to commercial leadership

Idorsia holds its Annual General Meeting of Shareholders

Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia

Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

Idorsia issues invitation to the 2023 Annual General Meeting of Shareholders

On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder

Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company

Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension

Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany

Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award

The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand